Chestertons Global Expands Footprint Including New Offices Across the Caribbean, Europe and North Africa
6.5.2021 09:00:00 EEST | Business Wire | Press release
Global estate agency, Chestertons Global Franchise Holdings Limited, today announced that Chestertons Cyprus has joined its expanding network, which has seen rapid growth over the past year.
Since Chestertons Ionian, headquartered in Corfu, was welcomed on board as the first Global Franchise Partner in early March 2020, the business has gone from strength to strength, with new teams joining the Chestertons network in the following locations: Barbados, Antigua & Barbuda, Portugal, Morocco, the Costa del Sol, Gibraltar and now Cyprus.
Chestertons Cyprus, headed up by Principal Andrew Constantinou, has launched its first office in Paphos, with plans for additional offices in the works. With the Portugal and Costa del Sol openings bringing five offices apiece to the network, the new franchise offering has secured 16 offices in total to date, increasing the number of property listings on the global business’ books by 300%.
The expansion of the franchise business means Chestertons’ geographic reach (in terms of physical office presence) has expanded from 15 countries in Q1 2020 to 21 today, an increase of 40%.
Jamie McMullan, Chief Operating Officer, Chestertons Franchising UK & Europe, comments: “The marketing, technological and brand heritage clout which we offer our partners has proved highly attractive, equipping them with the network and tools to enhance their services. The franchising model also offers local experts the chance to grow their businesses, with the backing of a global network of expertise and support.
“Building on the impressive growth seen over the last year, our franchise offering is attracting interest from across Asia, the Americas and additional European locations. We continue to be on the lookout for like-minded partners that can share in our brand, technology and extensive international network.”
The Global New Homes team has also reported significant growth over the last year, as it strives to work with the most prestigious developers on globally renowned projects. In 2020 the team, headquartered in Dubai, introduced seven additional new homes desks including in Hong Kong and Qatar, further expanding their network of lifestyle purchasers and investors.
The number of locations marketed by the Global New Homes team on a country basis has increased by 30% in the last 12 months to now include Japan, Thailand, Greece and Cyprus. The volume of new developments on the team’s books is up 40% since the first quarter of 2020, and includes the exclusive marketing in the Middle East and North Africa region of Fairmont Royal Palm Marrakech, and working with the likes of Barratt London and EcoWorld to launch homes to markets in the Middle East.
All-in-all buyer enquires for new homes are up 15% annually (Q1 2020 vs Q1 2021).
Dennis Chan, Global Head of International Sales, comments: “Appetite for real estate remained robust over the past 12 months, albeit in a challenging global environment amid the pandemic. With vaccination programmes underway, there is now a sense the pandemic is easing and, with the possibility of international travel resuming over coming months, buyers can take advantage of citizenship programmes, remote working visas, or financial incentives offered by developers in sought after destinations across the world.
“In this context, our clients and buyers have seen renewed value in our offering, which deploys our global team’s diverse skillsets to make their lives as straightforward as possible in what can be a complex process.”
To learn more about global franchising opportunities go to: www.chestertons.com/franchising
ENDS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005826/en/
Contact information
Jamie Till
chestertons@instinctif.com / 0207 457 2020
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
